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ABSTRACT
Background: This article proposes an International
Parkinson and Movement Disorder Society (MDS)-
UPDRS tremor-based scale and describes its mea-
surement properties, with a view to developing an
improved scale for assessing tremor in Parkinson’s dis-
ease (PD).
Methods: This was a cross-sectional, multicenter study
of 435 PD patients. Rasch analysis was performed on
the 11 MDS-UPDRS tremor items. Construct validity,
precision, and test-retest reliability were also analyzed.
Results: After some modifications, which included
removal of an item owing to redundancy, the obtained
MDS-UPDRS tremor scale showed moderate reliability,
unidimensionality, absence of differential item function-
ing, satisfactory convergent validity with medication,
and better precision than the raw sum score. However,
the scale displayed a floor effect and a need for more
items measuring lower levels of tremor.
Conclusions: The MDS-UPDRS tremor scale provides
linear scores that can be used to assess tremor in PD in a
valid, reliable way. The scale might benefit from modifica-
tions and studies that analyze its responsiveness. VC 2015
International Parkinson and Movement Disorder Society
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Tremor is the most frequent initial motor symptom of
Parkinson’s disease (PD): 36% to 49% of patients have
tremor-dominant PD or a balance between tremor and
gait symptoms.1 Although efforts have been made to
develop valid, reliable scales to quantify tremor in essen-
tial tremor,2 there is no specific tremor scale for PD.
Several tremor items are included in the UPDRS, the
most widely used clinical rating scale in PD recently
revised as the International Parkinson and Movement
Disorder Society (MDS)-UPDRS.3 A study measured
PD tremor using the Tremor Index, using items rating
rest, postural, and action tremor.4 However, there was
no information about its psychometric properties
beyond construct validity.
Because the MDS-UPDRS scale is widely used and
includes several tremor items, the aim of this study was
to propose an improved tremor measure for PD. The
measurement properties of the MDS-UPDRS tremor scale
were assessed using Rasch analysis.5 Its advantages are to
capture important aspects of PD tremor, the use of MDS-
UPDRS items, and obtaining results in a linear measure.
Patients and Methods
Patients and Measures
A sample of 435 outpatients diagnosed with PD was
drawn from an observational, cross-sectional study in five
Spanish-speaking countries.6 Ethic committees of the par-
ticipating centers approved the study and patients provided
written informed consent. Details about the study are
described elsewhere.6 In a subsample of 51 stable patients,
the MDS-UPDRS was applied again, by the same rater, 7
to 14 days later Movement disorders specialists applied the
Spanish MDS-UPDRS6 and Hoehn and Yahr (H & Y)
staging.7
Statistical Analysis
A Rasch analysis was performed on 11 MDS-
UPDRS items that address tremor.8 One item belongs
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to Part II (2.10 tremor), and the others to Part III:
3.15a postural tremor-right hand; 3.15b postural
tremor-left hand; 3.16a kinetic tremor-right hand;
3.16b kinetic tremor-left hand; 3.17a rest tremor
amplitude-RUE; 3.17b rest tremor amplitude-LUE;
3.17c rest tremor amplitude-RLE; 3.17d rest tremor
amplitude-LLE; 3.17e rest tremor amplitude-lip/jaw;
and 3.18 constancy of rest tremor.
Rasch analysis models the probability of a specific
response as a function of person and items parameters
and allows ordering persons and items in the same
logit scale.5 Details are presented in Appendix 1 and
excellent Rasch analysis tutorials are available.9-11
Rasch analysis has several advantages over classical
methods: robustness against missing data; continuous
interval linear measure; known precision and accu-
racy; and using parametric statistics in lineal analy-
sis.12 After obtaining fit to the Rasch model, the
person locations were imported to the statistical soft-
ware IBM SPSS Statistics 19 (IBM Corp. Armonk,
NY). Test-retest reliability was calculated through
bidirectional random effects intraclass correlation
coefficient (ICC>0.7).13
For discriminant validity, we expected to find low
Pearson’s correlation coefficients (r<0.30) between
the tremor linear measure and each of the MDS-
UPDRS sections (Parts I–IV), corrected for item over-
lap.21,22 Coefficients of 0.30 to 0.59 were considered
as of moderate magnitude.14
For construct validity, patients on levodopa were
expected to have lower tremor values than the others
(independent t test).4 We also performed a post-hoc
comparison by disease duration (cutoff by the median,
7 years) and phenotype groups: tremor dominant or
postural instability/gait difficulty (PIGD).1 The mean
of MDS-UPDRS items 2.10, 3.15a-b, 3.16a-b, 3.17a-e,
and 3.18a was divided by the mean of the MDS-
UPDRS items 2.12, 2.13, 3.10-12. A ratio 1.15 indi-
cated tremor dominant and 0.90 PIGD.1
For precision, the standard error of measurement
[SEM5 SD(1–ICC)] was calculated.15 The SEM
should be <0.5 SD and the upper level of the 95%
confidence interval (CI) approaches the minimal
detectable change.15 For relative precision, we com-
pared the linear measure with the sum of item raw
scores in their ability in discriminating among groups
by medication and disease duration.17
Results
Mean6 standard deviation (M6SD) age was 66.716
10.32 years, 51.49% were males, with 11.1464.70
years of education. Disease duration was 8.5266.14
years, 80.5% of patients were treated with L-dopa as
monotherapy, and 61.8% were in H & Y stage 2. Only
one item had a missing value (0.2%).
To reach fit to the Rasch model, the following mod-
ifications were performed: response scale rescoring;
creation of super-items; and deletion of one item
(Appendices 1-4). The final model was satisfactory,
with no item bias (Table 1).
Given model fit to the Rasch, raw scores were
converted into an interval scale measure using a trans-
formation table (Appendix 3). The tremor scale had a
M6SD5 11.1316 5.390, range of 0 to 22.909,
skewness520.830, and SEM5 2.156 (upper 95%
CI5 4.222). For the rawscores: SEM52.176; SD5
5.736). For test-retest reliability, ICC50.856.
For the total group (Table 2), tremor scores were
significantly lower for patients taking L-dopa and with
higher disease duration (t test, p< 0.005). These dif-
ferences were not significant when using raw sum
scores, and the relative precision (3.218 and 6.627 for
medication and disease duration, respectively) favored
the linear measure. The correlation coefficients
between the tremor measure and the MDS-UPDRS
sections were close to zero (r520.091-0.038). The
correlation between the item 3.18 “constancy of rest
tremor” and the linear tremor measure scores was
0.674.
Approximately one third of patients (34.3%) were
tremor dominant (Table 2). In this group, the tremor
scale showed a low correlation with Parts I and II
(r5 0.27-0.29; P0.001) and moderate with Part III
TABLE 1. Fit of the tremor scale to the Rasch model
Ideal Values Initial Analysis Final Analysis
Number of items 11 7
Item residual Mean 0.0 21.005 20.858
SD <1.4 2.035 1.219
Person residual Mean 0.0 20.348 20.315
SD <1.4 0.866 0.785
Chi-square Value 150.961 91.358
P level >0.05/n. items <0.0001 0.011
PSI >0.70 0.764 0.614
Unidimensional test % (CI) (LCI <5%) 8.28 (0.062-0.103) 1.85 (20.002-0.039)
PSI, person separation index; LCI, lower confidence interval.
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(r50.44; P<0.001). There was a significant trend
(analysis of variance [ANOVA]: P5 0.002) with
tremor scores increasing with H & Y stages 1-3.
Discussion
Rest tremor is one of the cardinal signs of PD, and
most motor examination scales in PD include items
addressing tremor. This article aimed at proposing a scale
based on the MDS-UPDRS tremor items and assessing its
measurement properties using Rasch analysis.
The obtained scale was unidimensional, supporting
the use of sum scores as a global PD tremor measure.
The correlation between the item “constancy of rest
tremor” and the linear tremor measure scores indicates
a high convergent validity. A previous study also
showed that constancy of tremor, as measured with an
actigraph, was a good indicator of tremor severity.18
The MDS-UPDRS tremor scale presented a satisfac-
tory, but moderate, reliability, probably owing to a
small number of items and floor effect. However, this
instrument is useful to measure patients with higher
levels of tremor in PD. A floor effect for rest, postural,
and kinetic tremor has been documented for the previ-
ous version of the UPDRS.19 The person-item distribu-
tion suggests that more items are needed, especially
measuring lower tremor levels. In addition, the impact
of tremor on social functioning, a clinically important
problem in PD, is not captured by the MDS-UPDRS
scale. Given that almost all items of this scale are
rated by the clinician, the scale might benefit from the
addition of items centered on the patient’s perspective.
Items to be added, which could be drawn from other
tremor scales, should be assessed according to content
and overall purpose of the tool: assessing tremor in
PD patients.
Our study found evidence that, for each hand, the
scores of kinetic and postural tremor should be con-
sidered as a single item. This was also observed for
rest tremor amplitude of left and lower extremities.
A confirmatory factor analysis of the UPDRS motor
section also showed a high unexplained residual cor-
relation between these items.20 In addition, the
items’ hierarchy reflects the initial unilateral involve-
ment, which supports the content validity of the
scale.
TABLE 2. MDS-UPDRS tremor linear scores by sociodemographic and clinical variables, for the total sample, and tremor-
dominant and postural instability/gait difficulty groups
Total Sample Tremor Dominanta PGIDa
(n5 435) (n5 149) (n5239)
Mean SD P Value Mean SD p-value Mean SD P Value
Sex 0.729 0.718 0.475
Male 11.126 5.053 14.252 2.518 9.017 5.244
Female 10.633 5.807 14.414 2.912 8.496 5.953
Age, years 0.430 0.625 0.222
68 11.258 5.095 14.227 2.782 9.205 5.322
>68 10.495 5.739 14.446 2.585 8.318 5.842
Education level, years 0.446 0.761 0.945
11 11.028 5.511 14.386 2.541 8.790 5.820
>11 10.754 5.323 14.250 2.873 8.740 5.375
Medication (L-dopa) 0.003 0.629 0.976
No 12.446 4.252 14.196 2.010 8.796 5.434
Yes 10.808 5.592 14.396 3.020 8.761 5.623
Disease duration, years 0.004 0.206 0.500
7 11.633 4.635 14.106 2.395 9.056 4.997
>7 10.152 6.026 14.763 3.187 8.572 5.963
H & Y stage 0.277 0.002 0.001
1 11.658 3.906 12.942 2.635 8.388 4.782
2 10.915 5.361 14.544 2.595 7.632 5.099
3 9.741 5.990 16.574 2.288 9.090 5.830
4 11.931 5.916 — — 11.931 5.916
5 13.151 5.201 — — 13.151 5.201
Pearson correlations with MDS-UPDRS r P Value r P Value r P Value
Part I 0.022 0.650 0.267 0.001 0.170 0.008
Part II (without tremor item) 0.011 0.814 0.288 <0.001 0.304 <0.001
Part III (without tremor items) 0.038 0.432 0.437 <0.001 0.187 0.004
Part IV 20.091 0.060 0.049 0.555 0.145 0.025
For all group comparisons, t tests were used except for comparisons by H & Y (ANOVA).
a“Indeterminate” type patients were not included in the analyses because of its low frequency (n5 46).
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Our results support the measure’s construct validity
with other variables. As hypothesized, the tremor mea-
sure showed good discriminant validity with the
MDS-UPDRS sections. Tremor in PD is a relatively
independent sign/symptom, with a loose relationship
with other features.21,22 Another study, using the
UPDRS, revealed that tremor is significantly influenced
by age, but not gender.23 These results are partially
concordant with ours. Tremor scores were signifi-
cantly lower in patients taking L-dopa, which is con-
gruent with the tremor-beneficial medication effect.4
As in other studies, the linear measure showed a
lower SEM and better relative precision than the raw
scores.24 Thus, the use of the linear measure instead
of sum scores is recommended. More studies are
needed to fully evaluate the scale’s responsiveness.
Some limitations must be acknowledged. We did
not include an objective tremor measure, because our
study is based on secondary data analysis. Previous
studies show a significant, high-magnitude correlation
between the UPDRS 3.0 tremor items and objective
measures [19,23,25].19,23,25 In addition, information
about L-dopa equivalent daily dose was not available.
Although the scale’s responsiveness has not been for-
mally tested and longitudinal studies are needed, its
precision was adequate.15
In summary, the MDS-UPDRS tremor scale has sev-
eral strengths, but also some weaknesses. On one
hand, the MDS-UPDRS tremor scale is a short instru-
ment specific for PD tremor, using items already avail-
able, that provides a linear measure unbiased that is
by age, sex, and education. It is strictly unidimen-
sional, its reliability is moderate, it captures the later-
alization of tremor symptoms, has good construct
validity, and is a more precise measure than the raw
sum scores. On the other hand, the scale shows poten-
tial for improvement. The addition of more items tar-
geting low tremor levels would probably resolve its
floor effect and improve reliability. Modifications of
the scale would require further validation studies.
More research is needed to further evaluate the scale’s
validity and sensitivity to change.
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